Protocol for a randomized controlled trial on community education and surveillance on antibiotics use among young children in Nepal.
Antimicrobial resistance
Nepal
Randomized controlled trials
Journal
Contemporary clinical trials communications
ISSN: 2451-8654
Titre abrégé: Contemp Clin Trials Commun
Pays: Netherlands
ID NLM: 101671157
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
07
03
2023
revised:
18
06
2023
accepted:
19
06
2023
medline:
6
7
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
epublish
Résumé
Antimicrobial resistance (AMR) is one of the top ten threats to global health. There exists limited empirical evidence on effective approaches to address this threat. In low- and middle-income countries (LMICs), one of the primary drivers of AMR is easy access to antibiotics without prescriptions, in particular from community pharmacies. Interventions to reduce non-prescribed use of antibiotics and surveillance systems to track such usage are critically needed. This protocol describes a study that aims to test the effect of an educational intervention targeted to parents of young children on non-prescribed antibiotics consumption in Nepal and to track such consumption using a phone-based application. The study is a clustered randomized controlled trial, in which we randomly assign 40 urban wards of Kathmandu Valley to either treatment group or control group, and randomly select 24 households in each ward. Households in the treatment group will receive an education intervention consisting of an "AMR pitch" (an in-person interaction that lasts up to an hour) by community nurses, videos and text messages on AMR every two weeks, and a brochure. We will conduct a survey at baseline with the parents of children ages 6 months to 10 years and track consumption of antibiotics and health care use among these children for a period of 6 months using a phone-based application. While the study will primarily inform future policy and programmatic efforts to reduce AMR in Nepal, the study-both the education intervention and the surveillance system-can serve as a prototype for tackling AMR in other similar settings.
Sections du résumé
Background
UNASSIGNED
Antimicrobial resistance (AMR) is one of the top ten threats to global health. There exists limited empirical evidence on effective approaches to address this threat. In low- and middle-income countries (LMICs), one of the primary drivers of AMR is easy access to antibiotics without prescriptions, in particular from community pharmacies. Interventions to reduce non-prescribed use of antibiotics and surveillance systems to track such usage are critically needed. This protocol describes a study that aims to test the effect of an educational intervention targeted to parents of young children on non-prescribed antibiotics consumption in Nepal and to track such consumption using a phone-based application.
Methods
UNASSIGNED
The study is a clustered randomized controlled trial, in which we randomly assign 40 urban wards of Kathmandu Valley to either treatment group or control group, and randomly select 24 households in each ward. Households in the treatment group will receive an education intervention consisting of an "AMR pitch" (an in-person interaction that lasts up to an hour) by community nurses, videos and text messages on AMR every two weeks, and a brochure. We will conduct a survey at baseline with the parents of children ages 6 months to 10 years and track consumption of antibiotics and health care use among these children for a period of 6 months using a phone-based application.
Conclusion
UNASSIGNED
While the study will primarily inform future policy and programmatic efforts to reduce AMR in Nepal, the study-both the education intervention and the surveillance system-can serve as a prototype for tackling AMR in other similar settings.
Identifiants
pubmed: 37409187
doi: 10.1016/j.conctc.2023.101177
pii: S2451-8654(23)00123-0
pmc: PMC10318443
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101177Informations de copyright
© 2023 The Authors. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
S Afr Med J. 2015 Apr 06;105(5):325
pubmed: 26242647
EXCLI J. 2013 May 07;12:384-95
pubmed: 26622211
BMJ Glob Health. 2021 Nov;6(11):
pubmed: 34815242
Front Med (Lausanne). 2019 May 24;6:105
pubmed: 31179281
J Health Econ. 2011 Sep;30(5):933-49
pubmed: 21733587
Lancet Infect Dis. 2020 Feb;20(2):179-187
pubmed: 31843383
Technol Health Care. 2010;18(2):137-44
pubmed: 20495253
PLoS One. 2022 Aug 18;17(8):e0273380
pubmed: 35980986
BMJ Open. 2019 Oct 10;9(10):e032422
pubmed: 31601603
Pediatrics. 2012 May;129(5):950-60
pubmed: 22473366
Antibiotics (Basel). 2021 Aug 29;10(9):
pubmed: 34572634
Soc Sci Med. 2022 Dec;314:115466
pubmed: 36302296
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Lancet Infect Dis. 2011 Sep;11(9):692-701
pubmed: 21659004
J Nepal Health Res Counc. 2015 May-Aug;13(30):102-11
pubmed: 26744193
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
PLoS Biol. 2008 Nov 18;6(11):e280
pubmed: 19018661
BMJ Glob Health. 2016 Dec 19;1(4):e000050
pubmed: 28588974
Antibiotics (Basel). 2018 Dec 22;8(1):
pubmed: 30583566
AIDS. 2011 Mar 27;25(6):825-34
pubmed: 21252632
Health Aff (Millwood). 2022 Jun;41(6):911-920
pubmed: 35666967
PLoS One. 2013 Jun 12;8(6):e65772
pubmed: 23776544
Healthc (Amst). 2018 Sep;6(3):197-204
pubmed: 29880283
Br J Gen Pract. 2014 Dec;64(629):604-5
pubmed: 25452508
Health Policy Plan. 2021 Jun 3;36(5):594-605
pubmed: 33822953